Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: A retrospective cohort study

Annals of Allergy, Asthma and Immunology

Volumn 106, Issue 3, 2011, Pages

  Guo, Jeff J ^a   Tsai, Katherine ^b   Kelton, Christina M L ^c   Bian, Boyang ^a   Wigle, Patricia R ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FEXOFENADINE; FORMOTEROL; LORATADINE; METHYLXANTHINE; OMALIZUMAB; SALMETEROL;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ALCOHOL ABUSE; ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG USE; EMERGENCY WARD; FEMALE; HOSPITALIZATION; HUMAN; INFANT; INTUBATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; NEWBORN; OBESITY; PREGNANCY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SUBSTANCE ABUSE;

EID: 79952185258     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2010.12.008     Document Type: Article

References (28)

1. Braman SS. The global burden of asthma. Chest. 2006;130:4S-12S.
2. American Lung Association, Trends in asthma morbidity and mortality, January 2009. Available at http://www.lungusa.org/finding-cures/ forprofessionals/epidemiology-and-statistics-rpts.html. Accessed January 29, 2010.
3. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma (Expert Panel Review-3). August 28, 2007. Available at http://www.nhlbi.nih.gov/ guidelines/asthma/asthgdln.pdf. Accessed January 29, 2010.
4. Kemp JP, Bierman CW, Cocchetto DM. Dose -response study of inhaled salmeterol in asthmatic patients with 24 hour spirometry and Holter monitoring. Ann Allergy. 1993;70:316-322. (Pubitemid 23110026)
5. Derom EY, Pauwels RA, Van der Straeten ME. The effect of inhaled salmeterol on methacholine responsiveness in patients with asthma up to 12 h. J Allergy Clin Immunol. 1992;89:811-815.
6. Boyd G, Morice AH, Pousford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997;10:815-821. (Pubitemid 27180192)
7. National Heart, Lung, and Blood institute. National Asthma Education and Prevention Program Guidelines for the diagnosis and management of asthma: update on selected topics 2002. J Allergy Clin Immunol. 2002;110:S147-S219.
8. Currie GP, Lee DK, Lipworth BJ. Long-acting beta2-agonists in asthma: not so SMART? Drug Saf. 2006;29:647-656.
9. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J. 1993;306:1034-1037. (Pubitemid 23105961)
10. Nelson H, Weiss S, Bleecker E, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26. (Pubitemid 43265239)
11. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma related deaths. Ann Intern Med. 2006;144:904-912. (Pubitemid 46768131)
12. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583-2593. (Pubitemid 32479898)
13. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178:1009-1016.
14. Rodrigo G, Moral V, Marcos L, Castro-Rodriguez J. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma: a systematic review. Pulm Pharmacol Ther. 2009;22:9-19.
15. Bisgaard H. Effect of long-acting β2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol. 2003;36:391-398. (Pubitemid 37296699)
16. Kuehn BM. FDA Offers advice to reduce risks of long-acting beta agonists in asthma care. JAMA. 2010;303:1353-1354.
17. Heaton PC, Guo JJ, Cluxton RC, Jang R, Horning R. Analysis of the effectiveness and cost benefit of leukotriene modifiers in adults with asthma in the Ohio Medicaid population. J Manag Care Pharm. 2006;12:33-42. (Pubitemid 47400554)
18. Guo JJ, Jang R, Keller KK, McCracken A, Pan W, Cluxton RJ. Impact of school-based health centers on children with asthma. J Adol Health. 2005;37:266-274. (Pubitemid 41338013)
19. Busse WW, Maisiak R, Young KR Jr. Treatment regimen and side effects of treatment measures. Am J Respir Crit Care Med. 1994;149:S44-S50. (Pubitemid 24979665)
20. Johnson M. Molecular mechanisms of -2-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol. 2006;117:18-24. (Pubitemid 43017132)
21. Wechsler, ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta-2-adrenergic receptor polymorphism on response to longacting beta-2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled crossover trial. The Lancet. 2009;374:1754-1764.
22. Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J. 1995;130:572-579.
23. Bousquet J, Knani J, Henry C, Liard R, Richard A, et al. Undertreatment in a population of nonselected adult asthmatics. J Allerg Clin Immunol. 1996;98:514-521. (Pubitemid 26377916)
24. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allerg Clin Immunol. 1996;98:1016-1018. (Pubitemid 27014791)
25. Kuo A, Craig TJ. A retrospective study of risk factors for repeated admissions for asthma in a rural/suburban university hospital. J Am Osteopath Assoc. 2001;101:S14-S17; quiz S517-S518.
26. Hessel PA, Mitchell I, Tough S, et al. Risk factors for death from asthma: Prairie Provinces Asthma Study Group. Ann Allergy Asthma Immunol. 1999;83:362-368.
27. Lozano P, Connell FA, Koepsell TD. Use of health services by African-American children with asthma on Medicaid. JAMA. 1995;274:469-473.
28. Zoratti EM, Havstad S, Rodriguez J, et al. Health care service use by African-Americans and Caucasians with asthma in a managed care setting. Am J Respir Crit Care Med. 1998;158:371-377. (Pubitemid 28378161)